Cisplatin Binding and Inactivation of Mitochondrial Glutamate Oxaloacetate Transaminase in Cisplatin-Induced Rat Nephrotoxicity
Open Access
- 23 August 2013
- journal article
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 77 (8) , 1645-1649
Abstract
Cisplatin is a widely used chemotherapeutic agent, but its use is limited by nephrotoxicity associated with mitochondrial dysfunction. Because its mechanisms are poorly understood, we aimed to identify the mitochondrial proteins targeted by cisplatin. We isolated renal mitochondrial proteins from Sprague-Dawley (SD) rats and performed cisplatin-affinity column chromatography. The proteins eluted were detected on SDS–PAGE and subjected to in-gel tryptic digestion and LC-MS/MS analysis. We identified glutamate oxaloacetate transaminase (GOT) and mitochondrial malate dehydrogenase (MDH). Next, we administered cisplatin intraperitoneally to SD rats to induce nephrotoxicity and assayed the activities of the enzymes. The results indicated that cisplatin caused a severe decrease in mitochondrial GOT activity on day 1 after cisplatin administration. Three d later, we also identified a decrease in mitochondrial MDH activity. Our results indicate that cisplatin binds to mitochondrial GOT and inhibits its activity, ...Keywords
This publication has 37 references indexed in Scilit:
- Daintain/AIF-1 Reinforces the Resistance of Breast Cancer Cells to CisplatinBioscience, Biotechnology, and Biochemistry, 2012
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPharmacological Reviews, 2012
- Integrated epigenomic analysis sheds light on role of BMP4 in regulating cisplatin sensitivity in gastric cancerNature Reviews Gastroenterology & Hepatology, 2012
- Elastic response and length change of single DNA molecules induced by a combination of cisplatin and transplatinPhysical Review E, 2012
- Cisplatin more effective when given less oftenNature Reviews Clinical Oncology, 2011
- An integrative view of the pathophysiological events leading to cisplatin nephrotoxicityCritical Reviews in Toxicology, 2011
- Gemcitabine alone or plus cisplatin for biliary tract cancer?Nature Reviews Clinical Oncology, 2010
- Cisplatin combinations in cervical cancer—which is best?Nature Reviews Clinical Oncology, 2010
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Cancer therapy and renal injuryJournal of Clinical Investigation, 2002